A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma

Trial Profile

A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs DKN 01 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2018 Preliminary results presented in a Leap Therapeutics Media Release.
    • 16 Apr 2018 According to a Leap Therapeutics media release, preliminary results from the dose escalation phase of this study presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting.
    • 23 Feb 2018 According to a Leap Therapeutics media release, interim data are expected in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top